Stocktoria
SINOVAC BIOTECH LTD SVA
SINOVAC BIOTECH LTD financials (annual)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $386.0M | $361.4M | $470.2M | $1.5B | $19.4B | $510.6M | $246.1M | $229.7M | $174.3M | $72.4M |
| Gross profit | $262.0M | $220.7M | $323.3M | $815.2M | $18.4B | $443.4M | $213.6M | $204.9M | $154.1M | $50.0M |
| R&D expense | $216.2M | $270.7M | $350.2M | $478.7M | $152.7M | $48.8M | $24.3M | $21.9M | $20.5M | $12.6M |
| SG&A expense | $333.0M | $420.9M | $598.2M | $836.1M | $602.1M | $176.5M | $121.5M | $137.0M | $87.4M | $42.0M |
| Operating income | -$490.1M | -$505.5M | -$714.0M | -$509.0M | $17.6B | $215.6M | $68.6M | $45.3M | $45.4M | $504,000 |
| Income tax | -$63.3M | $2.2M | $36.4M | $11.5M | $3.4B | $31.4M | $5.6M | $10.5M | $8.3M | $2.7M |
| Net income | — | — | -$13.5M | $14.5M | $8.1B | $110.4M | $44.9M | $21.8M | $25.8M | -$596,000 |
| EPS (diluted) | $-0.83 | $1.27 | $-0.19 | $0.20 | $113.44 | $0.97 | $0.41 | $0.34 | $0.45 | $-0.01 |
| Operating cash flow | -$512.2M | -$56.9M | $138.6M | -$798.1M | $15.3B | $479.3M | $39.1M | $7.9M | $59.8M | -$13.9M |
| Free cash flow | -$561.1M | -$152.9M | -$17.5M | -$1.1B | $14.7B | $351.8M | $28.4M | $2.3M | $47.8M | -$26.6M |
| Cash & equivalents | $488.2M | $335.3M | $1.1B | $3.9B | $11.6B | $1.0B | $152.7M | $158.2M | $114.4M | $62.4M |
| Inventory | $94.3M | $96.9M | $135.6M | $175.3M | $391.1M | $105.8M | $27.8M | $25.1M | $19.6M | $14.1M |
| Total assets | $8.5B | $12.3B | $13.6B | $14.0B | $16.8B | $1.9B | $452.3M | $369.8M | $299.2M | $211.4M |
| Total liabilities | $2.1B | $2.0B | $2.0B | $1.8B | $3.2B | $781.2M | $100.1M | $77.9M | $122.1M | $81.7M |
| Shareholders' equity | $6.4B | $10.3B | $11.6B | $12.2B | $13.6B | $1.1B | $352.2M | $291.9M | $177.1M | $129.7M |
Growth · year-over-year · Revenue CAGR 20.4%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | +6.8% | -23.1% | -68.1% | -92.4% | +3692.5% | +107.5% | +7.1% | +31.7% | +140.7% | — |
| Net income growth | — | — | -193.3% | -99.8% | +7259.1% | +145.7% | +106.3% | -15.6% | — | — |
| EPS growth | -165.4% | — | -195.0% | -99.8% | +11594.8% | +136.6% | +20.6% | -24.4% | — | — |
| Free cash flow growth | — | — | — | -107.6% | +4086.1% | +1136.8% | +1120.9% | -95.1% | — | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.